All In Biotech

Drug Trial Radar · NCT06975865

The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Flexible-adaptive, Group Sequential Study to Evaluate the Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

192

Planned (sponsor's estimate)

Start

Aug 12, 2025

Primary completion

Jul 23, 2027

Study completion Dec 29, 2028

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
May 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study details include: * Study duration: a 52-week double-blind period (Part A), followed by an open-label LTE period (Part B). Double-blind period has two parts, 50% (adult only) until the interim analysis (a proof-concept part analogous to a phase 2b study), and 50% (adult and children) after the interim analysis. Only the participants who complete double-blind treatment period (Part A) are eligible to continue to the LTE period. The duration of the LTE period (Part B) will be from the first-participant-in (FPI)-LTE (Part B) until the last participant who enters the LTE has completed 52 weeks. * Treatment duration: 52-week double-blind period (Part A); LTE period (Part B) from the (FPI until the last participant who enters the LTE has completed 52 weeks. * Visit frequency: Week visits based on the Schedule of Assessments.

Conditions

  • Sickle Cell Disease

Interventions

  • RilzabrutinibDrug

    Pharmaceutical form:Tablet -Route of administration:Oral

  • PlaceboDrug

    Pharmaceutical form:Tablet -Route of administration:Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized rate of clinical VOCTime frame: At Week 52

Locations

64 sites in 14 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham- Site Number : 8400003

    Birmingham, Alabama · Recruiting

  • Phoenix Children's Hospital- Site Number : 8400028

    Phoenix, Arizona · Recruiting

  • University of California San Francisco- Site Number : 8400040

    Clovis, California · Recruiting

  • David Geffen School of Medicine at UCLA- Site Number : 8400032

    Los Angeles, California · Recruiting

  • MedStar Georgetown University Hospital- Site Number : 8400036

    Washington D.C., District of Columbia · Recruiting

  • Oncology & Hematology Associates of West Broward- Site Number : 8400029

    Coral Springs, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center- Site Number : 8400020

    Miami, Florida · Recruiting

  • University of Illinois-Chicago - College of Medicine- Site Number : 8400054

    Chicago, Illinois · Recruiting

  • Indiana University Health Riley Hospital for Children- Site Number : 8400056

    Indianapolis, Indiana · Recruiting

  • Louisiana State University Health Sciences Center - Shreveport- Site Number : 8400037

    Shreveport, Louisiana · Recruiting

  • University of Maryland School of Medicine - Baltimore- Site Number : 8400041

    Baltimore, Maryland · Recruiting

  • University of Michigan Health System - Ann Arbor- Site Number : 8400035

    Ann Arbor, Michigan · Recruiting

  • Southern Specialty Research- Site Number : 8400059

    Flowood, Mississippi · Recruiting

  • Richmond University Medical Center- Site Number : 8400038

    Staten Island, New York · Recruiting

  • Montefiore Medical Center - Moses Campus- Site Number : 8400057

    The Bronx, New York · Recruiting

  • Oregon Health & Science University (OHSU)- Site Number : 8400043

    Portland, Oregon · Recruiting

  • Prisma Health- Site Number : 8400051

    Greenville, South Carolina · Recruiting

  • University of Tennessee Health Science Center- Site Number : 8400045

    Memphis, Tennessee · Recruiting

  • Baylor College of Medicine- Site Number : 8400055

    Houston, Texas · Recruiting

  • UT Physicians - Memorial Hermann- Site Number : 8400052

    Houston, Texas · Recruiting

  • VCU Massey Cancer Center: Dalton Oncology Clinic- Site Number : 8400012

    Richmond, Virginia · Recruiting

  • Investigational Site Number : 0560003

    Brussels, Belgium · Recruiting

  • Investigational Site Number : 0560002

    Brussels, Belgium · Recruiting

  • Investigational Site Number : 0560001

    Leuven, Belgium · Recruiting

  • Investigational Site Number : 0560004

    Liège, Belgium · Recruiting

  • Hospital Samaritano De Sao Paulo- Site Number : 0760005

    São Paulo, Brazil · Recruiting

  • Hospital Santa Izabel- Site Number : 0760006

    Salvador, Estado de Bahia, Brazil · Recruiting

  • Fundação Bahiana de Infectologia- Site Number : 0760009

    Salvador, Estado de Bahia, Brazil · Recruiting

  • Universidade Federal de Goias- Site Number : 0760002

    Goiânia, Goiás, Brazil · Recruiting

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto- Site Number : 0760001

    São José do Rio Preto, São Paulo, Brazil · Recruiting

  • Investigational Site Number : 2500002

    Créteil, France · Recruiting

  • Investigational Site Number : 2500005

    Marseille, France · Recruiting

  • Investigational Site Number : 2500001

    Paris, France · Recruiting

  • Investigational Site Number : 2500004

    Toulouse, France · Recruiting

  • Investigational Site Number : 2760005

    Berlin, Germany · Recruiting

  • Investigational Site Number : 2760002

    Essen, Germany · Recruiting

  • Investigational Site Number : 2760004

    Stuttgart, Germany · Recruiting

  • Investigational Site Number : 3000001

    Athens, Greece · Recruiting

  • Investigational Site Number : 3000003

    Athens, Greece · Recruiting

  • Investigational Site Number : 3000002

    Pátrai, Greece · Recruiting

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.